# GVM±R in Patients With Relapsed or Refractory Aggressive NHL

> **NCT05299164** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 18 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Liposomal Mitoxantrone Hydrochloride dose level 1
- **DRUG:** Liposomal Mitoxantrone Hydrochloride dose level 2
- **DRUG:** Liposomal Mitoxantrone Hydrochloride dose level 3
- **DRUG:** Liposomal Mitoxantrone Hydrochloride dose level 4

## Key facts

- **NCT ID:** NCT05299164
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-15
- **Primary completion:** 2023-12-18
- **Final completion:** 2025-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299164, "GVM±R in Patients With Relapsed or Refractory Aggressive NHL". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05299164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*